Lundbeck and Otuska’s brexpiprazole hits the mark in PTSD trial by Nick Paul Taylor Friday, November 30, 2018 The data give Lundbeck a boost at a time when its recently installed CEO is hunting for ways to improve on lackluster growth forecasts.
Lundbeck schizophrenia drug fails phase 3, sinking stock by Nick Paul Taylor Friday, October 26, 2018 The setback to the mooted blockbuster wiped around 30% off Lundbeck’s stock price.
After seeing POC data, Kyowa advances Parkinson’s program by Nick Paul Taylor Monday, August 20, 2018 Kyowa Hakko Kirin has posted a look at proof-of-concept data on adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease patients.
Lundbeck to buy Prexton for phase 2 Parkinson’s drug by Nick Paul Taylor Friday, March 16, 2018 The buyout gives Lundbeck control of an mGluR4 positive allosteric modulator designed to improve the long-term symptom control of dopaminergic agents.
Chutes & Ladders—Teva taps Lundbeck chief with $52M package by Angus Liu Friday, September 15, 2017 Lundbeck chief Schultz will lead Teva, former CDC director Frieden leads a new health project, Roivant named Eisai exec Waxman as general counsel.
Merck halts Alzheimer’s phase 3 after interim data analysis by Nick Paul Taylor Wednesday, February 15, 2017 Merck has halted a phase 2/3 Alzheimer’s disease trial after an interim analysis found it was destined to fail.
Lundbeck calls time on Alzheimer’s drug after more failures by Nick Paul Taylor Wednesday, February 8, 2017 Lundbeck is calling time on development of Alzheimer’s candidate idalopirdine after it chalked up a clean sweep of failures in phase 3.
Lundbeck inks deal for BBB-crossing shark antibody assets by Nick Paul Taylor Friday, January 27, 2017 Lundbeck has struck a deal with Ossianix to use shark-derived antibodies to hustle drugs across the blood-brain barrier.
Lundbeck, Takeda drug fails to best placebo in ADHD PhII by Nick Paul Taylor Wednesday, November 2, 2016 Lundbeck and Takeda's Brintellix has failed to beat the placebo in a Phase II trial in adult ADHD patients
PhIII Alzheimer’s flop takes chunk out of Lundbeck, hits Axovant with aftershocks by Nick Paul Taylor Friday, September 23, 2016 Lundbeck has chalked up another Phase III failure for the Alzheimer's field. Neither dose hit the primary endpoint or showed separation from placebo.